Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![NotAnotherFlow Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1832865338238873600.png) Charles [@NotAnotherFlow](/creator/twitter/NotAnotherFlow) on x 2586 followers
Created: 2025-07-13 21:13:44 UTC

$APLS – Large $600K buyer of XXXXX $XX calls for 10/17

Not the best looking chart. Apellis is another biopharma company. 

Key Event - A supplemental NDA is under Priority Review with a July 28, 2025 PDUFA date. If approved, a U.S. launch is expected in the second half of 2025.

![](https://pbs.twimg.com/media/GvxCj5aaAAAoKF5.jpg)

XXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1944505547103060182/c:line.svg)

**Related Topics**
[approved](/topic/approved)
[$600k](/topic/$600k)
[$apls](/topic/$apls)

[Post Link](https://x.com/NotAnotherFlow/status/1944505547103060182)

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

NotAnotherFlow Avatar Charles @NotAnotherFlow on x 2586 followers Created: 2025-07-13 21:13:44 UTC

$APLS – Large $600K buyer of XXXXX $XX calls for 10/17

Not the best looking chart. Apellis is another biopharma company.

Key Event - A supplemental NDA is under Priority Review with a July 28, 2025 PDUFA date. If approved, a U.S. launch is expected in the second half of 2025.

XXXXX engagements

Engagements Line Chart

Related Topics approved $600k $apls

Post Link

post/tweet::1944505547103060182
/post/tweet::1944505547103060182